Kidney Transplant Rejection

Nephrology
11
Pipeline Programs
6
Companies
16
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
7
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

Novartis
AFINITORApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2009
Novartis
AFINITOR DISPERZApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2012
U
EVEROLIMUSApproved
everolimus
Unknown Company
oral2025
Novartis
ZORTRESSApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2010

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Genomics
GenomicsUK - Oxford
8 programs
1
AllosurePhase 41 trial
Diagnostic Test: TruGraf® TestingN/A1 trial
Patients monitored with OmniGraf testingN/A1 trial
Patients monitored with TruGraf and TRAC testingN/A1 trial
Patients monitored with TruGraf and TRAC testingN/A1 trial
+3 more programs
Active Trials
NCT04398498Unknown50Est. Nov 2022
NCT05482100Not Yet Recruiting500Est. Jun 2026
NCT05335538Unknown75Est. Mar 2023
+5 more trials
Veloxis Pharmaceuticals
2 programs
1
1
Extended-release tacrolimusPhase 41 trial
Tacrolimus Extended Release Oral Tablet [Envarsus]Phase 11 trial
Active Trials
NCT03380936TerminatedEst. Oct 2019
NCT04225988CompletedEst. Jul 2023
Novartis
NovartisBASEL, Switzerland
1 program
1
EverolimusPhase 41 trial
Active Trials
NCT02974686Terminated1Est. Sep 2019
Hansa Biopharma
Hansa BiopharmaSweden - Lund
2 programs
1
ImlifidasePhase 21 trial
ImlifidaseN/A1 trial
Active Trials
NCT04711850TerminatedEst. Mar 2023
NCT03897205CompletedEst. Nov 2022
Eledon Pharmaceuticals
2 programs
2
AT-1501Phase 21 trial
AT-1501Phase 21 trial
Active Trials
NCT06126380Enrolling By InvitationEst. Dec 2029
NCT05983770CompletedEst. Sep 2025
One Biosciences
One BiosciencesFrance - Paris
1 program
MMDxN/A1 trial
Active Trials
NCT04239703RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
GenomicsAllosure
Veloxis PharmaceuticalsExtended-release tacrolimus
NovartisEverolimus
Eledon PharmaceuticalsAT-1501
Eledon PharmaceuticalsAT-1501
Hansa BiopharmaImlifidase
Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]
GenomicsPatients monitored with OmniGraf testing
GenomicsPatients monitored with TruGraf and TRAC testing
GenomicsTruGraf
Hansa BiopharmaImlifidase
GenomicsPatients monitored with TruGraf and TRAC testing
GenomicsTruGraf Testing - Peripheral blood gene expression profiling
GenomicsDiagnostic Test: TruGraf® Testing
GenomicsTruGraf® Testing

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 2,763 patients across 16 trials

NCT04177095GenomicsAllosure

Immune Monitoring to Facilitate Belatacept Monotherapy

Start: Feb 2020Est. completion: Jun 202317 patients
Phase 4Completed
NCT04225988Veloxis PharmaceuticalsExtended-release tacrolimus

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

Start: Jan 2020Est. completion: Jul 2023
Phase 4Completed
NCT02974686NovartisEverolimus

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Start: Nov 2016Est. completion: Sep 20191 patients
Phase 4Terminated
NCT06126380Eledon PharmaceuticalsAT-1501

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Start: Oct 2023Est. completion: Dec 2029
Phase 2Enrolling By Invitation
NCT05983770Eledon PharmaceuticalsAT-1501

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Start: Aug 2023Est. completion: Sep 2025
Phase 2Completed
NCT03897205Hansa BiopharmaImlifidase

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Start: Apr 2019Est. completion: Nov 2022
Phase 2Completed
NCT03380936Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Start: Jan 2018Est. completion: Oct 2019
Phase 1Terminated
NCT05482100GenomicsPatients monitored with OmniGraf testing

CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients

Start: Sep 2022Est. completion: Jun 2026500 patients
N/ANot Yet Recruiting
NCT05335538GenomicsPatients monitored with TruGraf and TRAC testing

TruGraf and TRAC In Pediatrics Study

Start: Nov 2021Est. completion: Mar 202375 patients
N/AUnknown
NCT04670926GenomicsTruGraf

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

Start: Jun 2021Est. completion: Sep 202375 patients
N/AUnknown
NCT04711850Hansa BiopharmaImlifidase

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Start: Jan 2021Est. completion: Mar 2023
N/ATerminated
NCT04491552GenomicsPatients monitored with TruGraf and TRAC testing

TruGraf® Long-term Clinical Outcomes Study

Start: Sep 2020Est. completion: Nov 20232,000 patients
N/AUnknown
NCT04267016GenomicsTruGraf Testing - Peripheral blood gene expression profiling

Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

Start: Aug 2020Est. completion: May 202126 patients
N/ATerminated
NCT04398498GenomicsDiagnostic Test: TruGraf® Testing

Molecular Biomarkers in Renal Transplantation Via TruGraf® Test

Start: Apr 2020Est. completion: Nov 202250 patients
N/AUnknown
NCT04266613GenomicsTruGraf® Testing

TruGraf® Testing in High-Risk Kidney Transplant Recipients

Start: Feb 2020Est. completion: Jun 202119 patients
N/ATerminated
NCT04239703One BiosciencesMMDx

Trifecta-Kidney cfDNA-MMDx Study

Start: Dec 2019Est. completion: Dec 2027
N/ARecruiting

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,763 patients
6 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Acute Kidney Injury(16)